Look out Amryt: Krystal’s topical gene therapy is gaining ground.
November approval decisions loom for cilta-cel and Voxzogo, while molnupiravir heads for an advisory panel.
Among developers that arrived on the market via reverse mergers, big success stories are hard to find.
Amryt marches ahead, but gene therapies from Krystal, Abeona and Castle Creek are heading towards data readouts.
Our final look at third-quarter events focuses this time on the smallest players, with data from Amryt, Ovid, Bellus and more.
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.